GSK 568893A

Drug Profile

GSK 568893A

Alternative Names: GSK-568893A; Human papillomavirus (types 16, 18, 31, 45) L1 virus-like particle vaccine - GlaxoSmithKline; Human papillomavirus (types 16, 18, 31, 45) L1 VLP vaccine - GlaxoSmithKline; Human papillomavirus quadrivalent (types 16, 18, 31, 45) recombinant vaccine - GlaxoSmithKline; Tetravalent HPV L1 16/18/31/45 virus-like particle vaccine - GlaxoSmithKline

Latest Information Update: 12 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Cancer vaccines; Papillomavirus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cervical cancer; Human papillomavirus infections

Most Recent Events

  • 12 May 2014 Discontinued - Phase-II for Cervical cancer in Belgium (IM)
  • 12 May 2014 Discontinued - Phase-II for Cervical cancer in USA (IM)
  • 12 May 2014 Discontinued - Phase-II for Human papillomavirus infections in Belgium (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top